MA43094B1 - Dérivés de maytansinoïde, leurs conjugués, et procédés d'utilisation - Google Patents

Dérivés de maytansinoïde, leurs conjugués, et procédés d'utilisation

Info

Publication number
MA43094B1
MA43094B1 MA43094A MA43094A MA43094B1 MA 43094 B1 MA43094 B1 MA 43094B1 MA 43094 A MA43094 A MA 43094A MA 43094 A MA43094 A MA 43094A MA 43094 B1 MA43094 B1 MA 43094B1
Authority
MA
Morocco
Prior art keywords
conjugates
methods
maytansinoid derivatives
maytansinoid
derivatives
Prior art date
Application number
MA43094A
Other languages
English (en)
Other versions
MA43094A1 (fr
Inventor
Thomas Nittoli
Thomas P Markotan
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of MA43094A1 publication Critical patent/MA43094A1/fr
Publication of MA43094B1 publication Critical patent/MA43094B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/537—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines spiro-condensed or forming part of bridged ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • C07K16/3092—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated mucins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Reproductive Health (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicinal Preparation (AREA)

Abstract

La présente invention concerne des dérivés de maytansinoïde, des conjugués de ceux-ci, et des procédés de traitement ou de prévention de maladies prolifératives à l'aide de ceux-ci.
MA43094A 2016-01-25 2017-01-24 Dérivés de maytansinoïde, leurs conjugués, et procédés d'utilisation MA43094B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662286858P 2016-01-25 2016-01-25
PCT/US2017/014782 WO2017132173A1 (fr) 2016-01-25 2017-01-24 Dérivés de maytansinoïde, leurs conjugués, et procédés d'utilisation

Publications (2)

Publication Number Publication Date
MA43094A1 MA43094A1 (fr) 2019-06-28
MA43094B1 true MA43094B1 (fr) 2020-10-28

Family

ID=57995285

Family Applications (1)

Application Number Title Priority Date Filing Date
MA43094A MA43094B1 (fr) 2016-01-25 2017-01-24 Dérivés de maytansinoïde, leurs conjugués, et procédés d'utilisation

Country Status (18)

Country Link
US (4) US9950076B2 (fr)
EP (1) EP3408271B1 (fr)
JP (1) JP6934010B2 (fr)
KR (1) KR102885186B1 (fr)
CN (2) CN108779127B (fr)
AU (1) AU2017211120C1 (fr)
BR (1) BR112018014759B1 (fr)
CL (1) CL2018002012A1 (fr)
CO (1) CO2018008761A2 (fr)
EA (1) EA039072B9 (fr)
IL (1) IL260744B (fr)
MA (1) MA43094B1 (fr)
MX (1) MX390630B (fr)
MY (1) MY198605A (fr)
PH (1) PH12018501589B1 (fr)
SG (1) SG11201806322QA (fr)
WO (1) WO2017132173A1 (fr)
ZA (1) ZA201804593B (fr)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX379256B (es) 2013-03-15 2025-03-10 Regeneron Pharma Moleculas biologicamente activas, conjugados de las mismas, y usos terapeuticos.
KR102252925B1 (ko) 2013-08-26 2021-05-18 리제너론 파마슈티칼스 인코포레이티드 마크롤라이드 디아스테레오머를 포함하는 약제학적 조성물, 이의 합성 방법 및 치료학적 용도
EA034950B1 (ru) 2015-03-27 2020-04-09 Регенерон Фармасьютикалз, Инк. Производные майтанзиноида, их конъюгаты и способы использования
MY189159A (en) 2015-07-06 2022-01-29 Regeneron Pharma Multispecific antigen-binding molecules and uses thereof
WO2017132173A1 (fr) * 2016-01-25 2017-08-03 Regeneron Pharmaceuticals, Inc. Dérivés de maytansinoïde, leurs conjugués, et procédés d'utilisation
WO2017190079A1 (fr) 2016-04-28 2017-11-02 Regeneron Pharmaceuticals, Inc. Procédés de production de molécules multispécifiques se liant à l'antigène
TWI782930B (zh) 2016-11-16 2022-11-11 美商再生元醫藥公司 抗ｍｅｔ抗體，結合ｍｅｔ之雙特異性抗原結合分子及其使用方法
KR20250008984A (ko) 2017-05-18 2025-01-16 리제너론 파마슈티칼스 인코포레이티드 사이클로덱스트린 단백질 약물 접합체
FI3635009T3 (fi) 2017-06-07 2026-04-07 Regeneron Pharma Koostumuksia ja menetelmiä entsyymien internalisoimiseksi
MX2020004691A (es) 2017-11-07 2020-08-20 Regeneron Pharma Enlazadores hidrofilicos para conjugados anticuerpo-farmaco.
MX2020011487A (es) 2018-04-30 2020-12-07 Regeneron Pharma Anticuerpos y moleculas biespecificas de union al antigeno que se unen a her2 y/o aplp2, conjugados y usos de estos.
EP3793591A1 (fr) 2018-05-17 2021-03-24 Regeneron Pharmaceuticals, Inc. Anticorps anti-cd63, conjugués et leurs utilisations
JP2022500454A (ja) * 2018-09-17 2022-01-04 ストロ バイオファーマ インコーポレーテッド 抗葉酸受容体抗体コンジュゲートによる併用療法
JP7591503B2 (ja) 2018-12-21 2024-11-28 リジェネロン ファーマシューティカルズ，インク． リファマイシンアナログおよびその抗体薬物コンジュゲート
US20220040319A1 (en) 2019-02-21 2022-02-10 Regeneron Pharmaceuticals, Inc. Methods of treating ocular cancer using anti-met antibodies and bispecific antigen binding molecules that bind met
US11896682B2 (en) 2019-09-16 2024-02-13 Regeneron Pharmaceuticals, Inc. Radiolabeled MET binding proteins for immuno-PET imaging and methods of use thereof
US11814428B2 (en) 2019-09-19 2023-11-14 Regeneron Pharmaceuticals, Inc. Anti-PTCRA antibody-drug conjugates and uses thereof
AU2020381495A1 (en) 2019-11-15 2022-05-19 Seagen Inc. Methods of treating HER2 positive breast cancer with tucatinib in combination with an anti-HER2 antibody-drug conjugate
IL295312A (en) 2020-02-28 2022-10-01 Regeneron Pharma Bispecific antigen binding molecules that bind her2, and methods of use thereof
IL319200A (en) 2020-04-16 2025-04-01 Regeneron Pharma Antibody-drug conjugates prepared using Diels-Alder compression methods
KR20240038138A (ko) 2020-07-13 2024-03-22 리제너론 파마슈티칼스 인코포레이티드 단백질에서 글루타민 잔기에 접합된 캄토테신 유사체 및 그의 용도
CA3191304A1 (fr) 2020-09-14 2022-03-17 Amy Han Conjugues anticorps-medicament comprenant des peptidomimetiques de glp1 et leurs utilisations
AU2021366691B2 (en) 2020-10-22 2024-06-06 Regeneron Pharmaceuticals, Inc. Anti-FGFR2 antibodies and methods of use thereof
CA3198294A1 (fr) 2020-11-10 2022-05-19 Thomas Nittoli Conjugues d'anticorps au selenium
CA3241734A1 (fr) 2022-01-12 2023-07-20 Amy Han Conjugues proteine-medicament comprenant des analogues de camptothecine et procedes d'utilisation associes
AU2023231305A1 (en) 2022-03-11 2024-09-12 Regeneron Pharmaceuticals, Inc. Anti-GLP1r antibody-tethered drug conjugates comprising GLP1 peptidomimetics and uses thereof
IL321285A (en) 2022-12-21 2025-08-01 Regeneron Pharma Topoisomerase I inhibitor prodrugs for ADC conjugates and a regimen for their use
CN116239607B (zh) * 2023-01-04 2024-04-09 山东大学 一种美登素衍生物及其生物合成方法与应用
US20250171516A1 (en) 2023-11-03 2025-05-29 Regeneron Pharmaceuticals, Inc. Peptide acids as a glp1r agonist and antibody-drug conjugates thereof
CN117257977A (zh) * 2023-11-07 2023-12-22 正大天晴药业集团南京顺欣制药有限公司 用于制备抗体药物偶联物的方法

Family Cites Families (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4307016A (en) * 1978-03-24 1981-12-22 Takeda Chemical Industries, Ltd. Demethyl maytansinoids
JPS5566585A (en) 1978-11-14 1980-05-20 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
US4263294A (en) * 1978-11-20 1981-04-21 Takeda Chemical Industries, Ltd. Maytansinoids, pharmaceutical compositions thereof and method of use thereof
JPS55102583A (en) * 1979-01-31 1980-08-05 Takeda Chem Ind Ltd 20-acyloxy-20-demethylmaytansinoid compound
CA2026147C (fr) 1989-10-25 2006-02-07 Ravi J. Chari Agents cytotoxiques comprenant des maytansinoides et leur usage therapeutique
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
US5714586A (en) 1995-06-07 1998-02-03 American Cyanamid Company Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates
US7087411B2 (en) 1999-06-08 2006-08-08 Regeneron Pharmaceuticals, Inc. Fusion protein capable of binding VEGF
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US20070258987A1 (en) 2000-11-28 2007-11-08 Seattle Genetics, Inc. Recombinant Anti-Cd30 Antibodies and Uses Thereof
US20090068178A1 (en) 2002-05-08 2009-03-12 Genentech, Inc. Compositions and Methods for the Treatment of Tumor of Hematopoietic Origin
DK2105135T3 (da) * 2002-05-17 2014-11-03 Celgene Corp Farmaceutiske sammensætninger til behandling af cancer
SI1545613T1 (sl) * 2002-07-31 2011-11-30 Seattle Genetics Inc Avristatinski konjugati in njihova uporaba za zdravljenje raka avtoimunske bolezni ali infekcijskebolezni
US20110250133A1 (en) 2003-01-13 2011-10-13 Bracco Imaging S.P.A. Gastrin releasing peptide compounds
US8088387B2 (en) 2003-10-10 2012-01-03 Immunogen Inc. Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
US7276497B2 (en) 2003-05-20 2007-10-02 Immunogen Inc. Cytotoxic agents comprising new maytansinoids
CN102558352A (zh) 2003-06-27 2012-07-11 艾默根佛蒙特有限公司 针对表皮生长因子受体的缺失突变体的抗体及其使用
GB0316294D0 (en) 2003-07-11 2003-08-13 Polytherics Ltd Conjugated biological molecules and their preparation
AR048098A1 (es) 2004-03-15 2006-03-29 Wyeth Corp Conjugados de caliqueamicina
CN1997402B (zh) * 2004-05-19 2014-04-02 梅达雷克斯有限责任公司 化学连接基团及其缀合物
KR20120064120A (ko) 2004-06-01 2012-06-18 제넨테크, 인크. 항체 약물 접합체 및 방법
EP1817341A2 (fr) 2004-11-29 2007-08-15 Seattle Genetics, Inc. Anticorps et immunoconjugues mis au point
NZ563370A (en) 2005-06-20 2010-10-29 Genentech Inc Compositions and methods for the diagnosis and treatment of tumor
NZ565075A (en) 2005-06-20 2011-05-27 Psma Dev Company Llc PSMA antibody-drug conjugates
US7750116B1 (en) 2006-02-18 2010-07-06 Seattle Genetics, Inc. Antibody drug conjugate metabolites
KR20140116546A (ko) 2006-10-27 2014-10-02 제넨테크, 인크. 항체 및 면역접합체 및 이들의 용도
NO347649B1 (no) 2006-12-14 2024-02-12 Regeneron Pharma Humant antistoff eller antistoff fragment som spesifikt binder human deltaliknende ligand 4 (hDII4), nukleinsyremolekyl som koder for slike og vektor og vert-vektorsystemer, samt fremgangsmåte for fremstilling, sammensetning og anvendelse.
WO2008122039A2 (fr) 2007-04-02 2008-10-09 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Molécules d'anticorps hybrides médiées par la sélénocystéine
EP2144628B1 (fr) 2007-05-08 2012-10-17 Genentech, Inc. Anticorps anti-muc16 produits avec de la cystéine et conjugués anticorps-médicament
JP2010528285A (ja) 2007-05-23 2010-08-19 ベンタナ・メデイカル・システムズ・インコーポレーテツド 免疫組織化学およびｉｎｓｉｔｕハイブリダーゼーションのためのポリマー担体
NZ602675A (en) 2008-03-18 2014-03-28 Genentech Inc Combinations of an anti-her2 antibody-drug conjugate and chemotherapeutic agents, and methods of use
EP2276506A4 (fr) 2008-04-30 2014-05-07 Immunogen Inc Conjugués puissants et coupleurs hydrophiles
CN102159248B (zh) * 2008-07-15 2013-09-11 健泰科生物技术公司 蒽环类衍生物缀合物、它们的制备方法以及它们作为抗肿瘤化合物的用途
EP2374481B1 (fr) 2008-07-21 2015-11-04 Polytherics Limited Nouveaux réactifs et procédé pour conjuguer des molécules biologiques
US9005598B2 (en) 2009-03-04 2015-04-14 Polytherics Limited Conjugated proteins and peptides
JO3182B1 (ar) 2009-07-29 2018-03-08 Regeneron Pharma مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2
JP5954789B2 (ja) 2009-08-10 2016-07-20 ユーシーエル ビジネス パブリック リミテッド カンパニー 機能的分子の可逆的共有結合
AR078471A1 (es) 2009-10-02 2011-11-09 Sanofi Aventis COMPUESTOS MAITANSINOIDES Y EL USO DE ESTOS PARA PREPARAR CONJUGADOS CON UN ANTICUERPO LOS CUALES SE UTILIZAN COMO AGENTES ANTICANCERIGENOS Y EL PROCEDIMIENTO DE PREPARACIoN DE ESTOS CONJUGADOS
EP2486023A4 (fr) 2009-10-06 2014-05-07 Immunogen Inc Conjugués puissants et séquences de liaison hydrophiles
US8501692B2 (en) 2009-12-14 2013-08-06 The Regents Of The University Of Michigan Compositions and methods for altering cocaine esterase activity
DK2528625T3 (da) 2010-04-15 2013-10-14 Spirogen Sarl Pyrrolobenzodiazepiner og konjugater deraf
US20130244905A1 (en) 2010-07-06 2013-09-19 Ed Grabczyk Reporter for RNA Polymerase II Termination
SG10201912639SA (en) 2010-08-02 2020-02-27 Regeneron Pharma Mice that make binding proteins comprising vl domains
MY162780A (en) 2010-09-01 2017-07-14 Bayer Ip Gmbh N-(Tetrazol-5-yl)- and N-(triazol-5-yl)arylcarboxamides and use thereof as herbicides
CN105399831A (zh) 2010-10-29 2016-03-16 伊缪诺金公司 非拮抗性egfr结合分子及其免疫偶联物
CN103269712B (zh) * 2010-11-03 2016-09-21 伊缪诺金公司 包含新型安丝菌素衍生物的细胞毒性剂
JP6215194B2 (ja) 2011-05-16 2017-10-18 コーニンクレッカ フィリップス エヌ ヴェＫｏｎｉｎｋｌｉｊｋｅ Ｐｈｉｌｉｐｓ Ｎ．Ｖ． 生体直交型薬物活性化
KR20140037105A (ko) 2011-05-27 2014-03-26 암브룩스, 인코포레이티드 비-천연 아미노산 연결된 돌라스타틴 유도체를 함유하는 조성물, 이를 수반하는 방법, 및 용도
US8815226B2 (en) 2011-06-10 2014-08-26 Mersana Therapeutics, Inc. Protein-polymer-drug conjugates
CN103648532A (zh) * 2011-06-21 2014-03-19 伊缪诺金公司 具有肽连接子的新型美登木素生物碱衍生物及其偶联物
CA2850096C (fr) 2011-10-14 2018-07-03 Spirogen Sarl Procede de synthese et intermediaires pouvant servir a preparer des pyrrolobenzodiazepines
ES2945932T3 (es) 2011-10-14 2023-07-10 Seagen Inc Pirrolobenzodiazepinas y conjugados dirigidos
WO2013055993A1 (fr) 2011-10-14 2013-04-18 Seattle Genetics, Inc. Pyrrolobenzodiazépines et conjugués ciblés
CA2850103C (fr) 2011-10-14 2019-09-10 Spirogen Sarl Pyrrolobenzodiazepines
WO2013068874A1 (fr) 2011-11-11 2013-05-16 Pfizer Inc. Conjugués anticorps-médicament
CN104244718A (zh) 2011-12-05 2014-12-24 伊格尼卡生物治疗公司 抗体-药物缀合物以及相关化合物、组合物和方法
GB201210770D0 (en) 2012-06-18 2012-08-01 Polytherics Ltd Novel conjugation reagents
MX2014015682A (es) 2012-06-19 2015-07-23 Polytherics Ltd Proceso novedoso para preparacion de conjugados de anticuerpo y conjugados de anticuerpo novedosos.
FI2911699T4 (fi) 2012-10-23 2025-12-09 Synaffix Bv Muokattu vasta-aine, vasta-ainekonjugaatti ja menetelmä niiden valmistamiseksi
NO2789793T3 (fr) 2012-10-24 2018-01-27
US10131682B2 (en) 2012-11-24 2018-11-20 Hangzhou Dac Biotech Co., Ltd. Hydrophilic linkers and their uses for conjugation of drugs to a cell binding molecules
TW201425336A (zh) 2012-12-07 2014-07-01 Amgen Inc Ｂｃｍａ抗原結合蛋白質
CN104688740A (zh) * 2012-12-21 2015-06-10 百奥泰生物科技(广州)有限公司 类美登素衍生物及其制备方法和用途
CN103254213B (zh) 2012-12-21 2015-02-25 百奥泰生物科技(广州)有限公司 类美登素酯的制备方法及用于所述方法的组合物
EP2764866A1 (fr) * 2013-02-07 2014-08-13 IP Gesellschaft für Management mbH Inhibiteurs de l'enzyme activant nedd8
MX379256B (es) 2013-03-15 2025-03-10 Regeneron Pharma Moleculas biologicamente activas, conjugados de las mismas, y usos terapeuticos.
CN103254311B (zh) 2013-05-09 2015-05-13 齐鲁制药有限公司 一种制备抗体-美登素类生物碱药物偶联物的方法
WO2014194030A2 (fr) 2013-05-31 2014-12-04 Immunogen, Inc. Conjugués comprenant des agents de liaison cellulaire et des agents cytotoxiques
WO2014197871A2 (fr) 2013-06-06 2014-12-11 Igenica Biotherapeutics, Inc. Conjugués anticorps-médicament, compositions et méthodes d'utilisation correspondantes
SG11201509982UA (fr) 2013-06-06 2016-04-28 Igenica Biotherapeutics Inc
US11229711B2 (en) 2013-06-06 2022-01-25 Magenta Therapeutics, Inc. Linkers for antibody-drug conjugates and related compounds, compositions, and methods of use
US10781259B2 (en) 2013-06-06 2020-09-22 Magenta Therapeutics, Inc. Modified antibodies and related compounds, compositions, and methods of use
US9545451B2 (en) 2013-08-21 2017-01-17 Regeneron Pharmaceuticals, Inc. Anti-PRLR antibodies and methods for killing PRLR-expressing cells
KR102252925B1 (ko) 2013-08-26 2021-05-18 리제너론 파마슈티칼스 인코포레이티드 마크롤라이드 디아스테레오머를 포함하는 약제학적 조성물, 이의 합성 방법 및 치료학적 용도
WO2015081282A1 (fr) 2013-11-27 2015-06-04 Redwood Bioscience, Inc. Composés hydrazinyl-pyrrolo et procédés de production d'un conjugué
US9562059B2 (en) 2013-12-02 2017-02-07 Hong Kong Baptist University Anticancer maytansinoids with two fused macrocyclic rings
CA2950155C (fr) 2014-06-02 2021-11-23 Regeneron Pharmaceuticals, Inc. Conjugues de molecules biologiquement actives, reactifs et methodes de fabrication, et utilisations therapeutiques
EA034950B1 (ru) 2015-03-27 2020-04-09 Регенерон Фармасьютикалз, Инк. Производные майтанзиноида, их конъюгаты и способы использования
WO2017132173A1 (fr) 2016-01-25 2017-08-03 Regeneron Pharmaceuticals, Inc. Dérivés de maytansinoïde, leurs conjugués, et procédés d'utilisation
MX2019003325A (es) 2016-09-23 2019-08-05 Regeneron Pharma Anticuerpos anti-steap2, conjugados anticuerpo-farmaco, y moleculas de fijacion al antigeno biespecificas que se fijan a steap2 y cd3, y usos de estos.
US11814428B2 (en) 2019-09-19 2023-11-14 Regeneron Pharmaceuticals, Inc. Anti-PTCRA antibody-drug conjugates and uses thereof

Also Published As

Publication number Publication date
CN114478801A (zh) 2022-05-13
EA201800444A1 (ru) 2019-04-30
CL2018002012A1 (es) 2018-08-31
US20180289834A1 (en) 2018-10-11
AU2017211120A1 (en) 2018-07-26
CO2018008761A2 (es) 2018-10-22
BR112018014759B1 (pt) 2024-02-27
JP2019502746A (ja) 2019-01-31
MX2018008987A (es) 2018-11-19
KR20180099892A (ko) 2018-09-05
BR112018014759A2 (en) 2018-12-11
WO2017132173A1 (fr) 2017-08-03
US20230116771A1 (en) 2023-04-13
JP6934010B2 (ja) 2021-09-08
AU2017211120B2 (en) 2021-04-01
KR102885186B1 (ko) 2025-11-17
US11446389B2 (en) 2022-09-20
US10463749B2 (en) 2019-11-05
PH12018501589A1 (en) 2019-04-08
MX390630B (es) 2025-03-21
US9950076B2 (en) 2018-04-24
EP3408271B1 (fr) 2023-01-11
EA039072B1 (ru) 2021-11-30
HK1257219A1 (en) 2019-10-18
EP3408271A1 (fr) 2018-12-05
US20200121806A1 (en) 2020-04-23
CN108779127A (zh) 2018-11-09
PH12018501589B1 (en) 2022-08-10
MA43094A1 (fr) 2019-06-28
SG11201806322QA (en) 2018-08-30
CA3011440A1 (fr) 2017-08-03
MY198605A (en) 2023-09-08
US20170209591A1 (en) 2017-07-27
CN108779127B (zh) 2022-07-05
IL260744B (en) 2021-03-25
AU2017211120C1 (en) 2021-10-07
ZA201804593B (en) 2022-12-21
EA039072B9 (ru) 2022-02-04
NZ744373A (en) 2025-03-28

Similar Documents

Publication Publication Date Title
MA43094B1 (fr) Dérivés de maytansinoïde, leurs conjugués, et procédés d'utilisation
MA44322A (fr) Compositions comprenant des souches bactériennes
MA42471A (fr) Compositions comprenant des souches bactériennes
EA201992546A1 (ru) Средства на основе антител к cd33
MA44890B1 (fr) Compositions comprenant des souches bactériennes
MA40513A (fr) Conjugués médicament-anticorps anti-cdh6
MA40754B1 (fr) Compositions comprenant des souches bactériennes
BR112017020149A8 (pt) Derivados de maitansinoide, conjugados dos mesmos e métodos de uso
MA40576B1 (fr) Anticorps et immunoconjugués anti-her2
MX390083B (es) Formulaciones de (r)-2-amino-3-fenilpropil carbamato.
MA41060A (fr) Compositions comprenant des souches bactériennes
MA55434A (fr) Compositions comprenant des souches bactériennes
MA40671A1 (fr) Anticorps anti-c10orf54 et leurs utilisations
MA40682A (fr) Anticorps anti-ox40 et procédés d'utilisation correspondants
MA41010A (fr) Compositions comprenant des souches bactériennes
MA48939A (fr) Compositions comprenant des souches bactériennes
BR112022000855A2 (pt) Moduladores de nlrp3
MA45999A (fr) Anticorps anti-pd-1, ou leurs fragments, pour le traitement de l'hépatite b
EP3331356A4 (fr) Fragments et dérivés de la progranuline (pgrn) pour le traitement ou le soulagement des maladies lysosomales
MA38654B1 (fr) Dérivés de type promédicament de triazolopyridines substituées
MA40844A (fr) Compositions pharmaceutiques à action prolongée pour l'hépatite c
MA41065B1 (fr) Dérivés de maytansinoïde, conjugués de ceux-ci, et procédés d'utilisation
MA39355A1 (fr) Anticorps anti-ox40 et procédés d'utilisation correspondants
TH1801004421A (th) อนุพันธุ์ของสาร Maytansinoid คอนจูเกต และวิธีการใช้
EA201992647A1 (ru) Композиции, содержащие бактериальные штаммы